AUG 31, 2020 4:36 AM PDT

A Treatment Avenue Opens for a Rare Disorder

WRITTEN BY: Carmen Leitch

Krabbe disease or globoid cell leukodystrophy is a rare disorder that affects about one in every 100,000 infants. It's caused by a mutation in a gene called GALC, which encodes an enzyme called galactosylceramidase. This incurable condition, which destroys the insulation surrounding nerve cells, is usually fatal to patients before age two.

Image credit: Pxhere

The disorder also affects dogs, who get symptoms starting around six weeks of age. It's also fatal for them; the dogs only survive for a few months after the onset of symptoms. Researchers have now used a canine model of Krabbe disease to show that gene therapy can eliminate the symptoms of the disease. Reporting in the Journal of Clinical Investigation (JCI), the scientists found that dogs that received the therapy lived to be at least four years old, apparently with no significant side effects.

"This disease has no good therapy," said senior study author Charles Vite, a professor of neurology. "We've been looking at this disease in dogs since the 1990s, but it was really the shift over to a new gene therapy vector that gave us a chance to treat it with a big effect on the nervous system."

Cells contain small organelles called lysosomes, they are sacs that contain digestive enzymes. Krabbe disease is a lysosomal storage disorder. Normally, the enzyme encoded by the GALC gene would break down lipids, but a mutated GALC enzyme cannot, so stuff builds up inside of the lysosomes. In the case of Krabbe disease, that disrupts the insulation or myelin surrounding nerve cells, which alters nerve signaling. The disorder leads to neurological symptoms, including blindness, deafness, and paralysis.

A risky bone marrow transplant in an infant patient's first month can help relieve the disorder, but it only works in thirty percent of those treated. "A new treatment is really needed," Vite said.

As with any gene therapy, getting the therapeutic materials to the right place in the body and cells poses a challenge. In this work, the scientists successfully used a viral vector that has been used in other gene therapies, the AAV9 vector, which seems likeliest to gain FDA approval. They tried using high and low doses of the therapy at various ages.

"We decided we would inject into the spinal fluid via the back of the head, which is the most effective means of getting to the brain," noted Vite.

The most benefit was seen in dogs that were given a high dose of gene therapy before they showed symptoms; they had more myelination in their brains, and the myelination in their peripheral nervous system was maintained (even though the therapy was injected into the central nervous system).

"That was a huge surprise for us; that injecting a gene therapy in the spinal fluid can positively affect both the central and the peripheral nervous system was really exciting," Vite said.

There was still a benefit for dogs that were treated after symptoms started. Though they had an intermediate form of the disease, they lived significantly longer than dogs that had not gotten any therapy. It shows that trials will have to be careful about the proper dose.

Follow-up studies will examine the molecular impacts of the therapy, as well as how to ensure both dogs and children receive the correct dose. Vite suggested that since this therapy triggered some improvement in the peripheral nervous system, the approach might be useful for other disorders.

"The hope is to use the model as a method to understand the mechanisms at work in peripheral nerves and how we can target peripheral neuropathies," said Vite.

Sources: AAAS/Eurekalert! via University of Pennsylvania, Journal of Clinical Investigation

About the Author
  • Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
OCT 15, 2020
Plants & Animals
Meet the World's First Cloned Przewalski's Horse
OCT 15, 2020
Meet the World's First Cloned Przewalski's Horse
Say “hello!” to Kurt, a two-month-old Przewalski’s horse that has made scientific history as the world ...
OCT 22, 2020
Cell & Molecular Biology
How a Gene Variant Raises the Risk of Multiple Sclerosis
OCT 22, 2020
How a Gene Variant Raises the Risk of Multiple Sclerosis
Now that sequencing the whole human genome is easier, faster, and cheaper than it used to be, scientists have been able ...
NOV 12, 2020
Cardiology
Creating a Mouse Model to Test RBM20 Dependent Dilated Cardiomyopathy
NOV 12, 2020
Creating a Mouse Model to Test RBM20 Dependent Dilated Cardiomyopathy
Cardiovascular disease is something that, in most cases, is within our ability to control. A healthy diet and active lif ...
DEC 13, 2020
Genetics & Genomics
Investigating the Many Nuclei in Muscle Cells
DEC 13, 2020
Investigating the Many Nuclei in Muscle Cells
Researchers led by Professor Carmen Birchmeier at the MDC have used a cutting-edge tool to learn more about different nu ...
DEC 28, 2020
Genetics & Genomics
Mapping Networks of Gene Expression in Cells
DEC 28, 2020
Mapping Networks of Gene Expression in Cells
Every cell contains our whole genome, but not all genes are turned on all the time; gene expression has to be very caref ...
JAN 18, 2021
Genetics & Genomics
The Weird Animal with Ten Sex Chromosomes
JAN 18, 2021
The Weird Animal with Ten Sex Chromosomes
The platypus is a near-threatened species from eastern Australia and Tasmania. It's considered a mammal because it grows ...
Loading Comments...